The Effect of SSRI Exposure in Pregnancy on Early Respiratory and Metabolic Adaptation in Infants Born Preterm
- PMID: 36980066
- PMCID: PMC10046952
- DOI: 10.3390/children10030508
The Effect of SSRI Exposure in Pregnancy on Early Respiratory and Metabolic Adaptation in Infants Born Preterm
Abstract
Selective serotonin reuptake inhibitors (SSRIs) are increasingly used for maternal depression during pregnancy; however, their use has been linked to adverse effects in newborns. Respiratory and feeding problems, jaundice, metabolic and temperature dysregulation and hypoglycemia have been described in term infants. However, scarce data exists on early neonatal adaptation in exposed infants born prematurely. We aimed to assess the effects of SSRI exposure on early neonatal adaptation measures in infants born prematurely. Data from preterm infants exposed to maternal SSRIs during pregnancy and from matched controls were retrospectively collected. Forty-two infants comprised the final cohort: 21 infants with SSRI exposure and 21 matched controls. 1 min Apgar score was significantly lower in the exposed group compared to the non-exposed group (p = 0.043). No differences were found in 5 min Apgar scores, cord pH, need for delivery room resuscitation, rate of hypoglycemia, hyponatremia, hyperbilirubinemia, need for phototherapy, temperature stability and maximal oxygen requirements. No differences were found in the total time of respiratory support, time to reaching full enteral feeds, length of stay and complications of prematurity. Unlike studies in term infants, no significant differences were found in adaptation and short-term outcomes between preterm infants with and without SSRI exposure in pregnancy.
Keywords: SSRI; early neonatal adaptation; preterm.
Conflict of interest statement
The authors declare no conflict of interest.
Similar articles
-
Effects of in-utero exposure to selective serotonin reuptake inhibitors and venlafaxine on term and preterm infants.J Neonatal Perinatal Med. 2017;10(4):371-380. doi: 10.3233/NPM-16133. J Neonatal Perinatal Med. 2017. PMID: 29286926
-
Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data.Arch Gen Psychiatry. 2006 Aug;63(8):898-906. doi: 10.1001/archpsyc.63.8.898. Arch Gen Psychiatry. 2006. PMID: 16894066
-
Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes.Am J Psychiatry. 2009 May;166(5):557-66. doi: 10.1176/appi.ajp.2008.08081170. Epub 2009 Mar 16. Am J Psychiatry. 2009. PMID: 19289451 Free PMC article.
-
Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and risk of preterm birth: a systematic review and meta-analysis.BJOG. 2016 Nov;123(12):1900-1907. doi: 10.1111/1471-0528.14144. Epub 2016 May 30. BJOG. 2016. PMID: 27239775 Free PMC article. Review.
-
Implementing intact cord resuscitation in very preterm infants: feasibility and pitfalls.Eur J Pediatr. 2023 Mar;182(3):1105-1113. doi: 10.1007/s00431-022-04776-2. Epub 2022 Dec 28. Eur J Pediatr. 2023. PMID: 36575308 Review.
Cited by
-
Practical Issues in the Treatment of Preterm Infants.Children (Basel). 2023 May 8;10(5):849. doi: 10.3390/children10050849. Children (Basel). 2023. PMID: 37238397 Free PMC article.
References
-
- Fischer Fumeaux C.J., Morisod Harari M., Weisskopf E., Eap C.B., Epiney M., Vial Y., Csajka C., Bickle Graz M., Panchaud A. Risk-benefit balance assessment of SSRI antidepressant use during pregnancy and lactation based on best available evidence—An update. Expert Opin. Drug Saf. 2019;18:949–963. doi: 10.1080/14740338.2019.1658740. - DOI - PubMed
-
- Grote N.K., Bridge J.A., Gavin A.R., Melville J.L., Iyengar S., Katon W.J. A meta-analysis of depression during pregnancy and the risk of preterm birth, low birth weight, and intrauterine growth restriction. Arch. Gen. Psychiatry. 2010;67:1012–1024. doi: 10.1001/archgenpsychiatry.2010.111. - DOI - PMC - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources